Estrogen for Triple Negative Breast Cancer

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine the effectiveness of Estradiol treatment for advanced breast cancer that is hormone receptor negative and Her2/neu negative. The study will also use tumor tissue from your original diagnosis or from a biopsy you may have had for your cancer to look at hormone receptors in the lab. The tissue left over from your previous surgery or a previous biopsy will be used for research tests to check whether a different estrogen receptor (estrogen receptor beta) is seen in the tumor and if that makes estrogen work better.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01083641
Study type	Interventional
Source	University of Wisconsin, Madison
Contact
Status	Terminated
Phase	Phase 2
Start date	January 2010
Completion date	March 2015

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT02480933` - Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens	N/A
Completed	`NCT05000502` - Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations	N/A
Not yet recruiting	`NCT04863833` - Tomosymthesis for Breast Mass Lesion Characterization
Recruiting	`NCT06145399` - A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer	Early Phase 1
Suspended	`NCT01320488` - Breast Cancer in Young Women: Is it Different?	N/A
Recruiting	`NCT02089854` - Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer	Phase 4
Active, not recruiting	`NCT01741883` - Side Effect Prevention Training (SEPT) for Nocebo Effects in Breast Cancer Patients	N/A
Recruiting	`NCT06144164` - A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer	Phase 3
Recruiting	`NCT06331793` - Pulsed Electromagnetic Fields for Analgesia Post Mastectomy	N/A
Recruiting	`NCT05439499` - This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.	Phase 3
Terminated	`NCT03836872` - Acupuncture for Joint Symptoms in Patients With Breast Cancer	N/A
Recruiting	`NCT06332976` - PrefeRences And ChemoTherapy In Breast Cancer patiEnts
Completed	`NCT01671319` - Dose Dense TC + Pegfilgrastim Support for Breast Cancer	Phase 2
Not yet recruiting	`NCT06092892` - IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases	Phase 2
Recruiting	`NCT05586256` - Ultra-hypofractionated Radiotherapy in Breast Cancer Patients
Not yet recruiting	`NCT03153631` - Female Sexual Dysfunction in Breast Cancer Patients	N/A
Active, not recruiting	`NCT03059875` - Place of Comprehensive Geriatric Assessment in Patients ≥ 75 Years Care, With Breast Cancer, After Screening With FOG (Oncology Geriatric Filter)	N/A
Active, not recruiting	`NCT02088710` - Expectations and Side Effects of Endocrine Therapy in Women With Breast Cancer	N/A
Recruiting	`NCT05374161` - An Intervention for Female Breast CANcer: Acceptance and Commitment Therapy (I-CAN-ACT) for Depression and Physical Pain	N/A
Recruiting	`NCT05438810` - This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c in Combination With Fluvestrant ± Goseraline Versus Placebo Combined With Fulvestrant ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.	Phase 3